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Supportive Therapy • Brief Report
High-dose (HD) cytarabine (Ara-C) iswidely used either as a single agent orin combination chemotherapy for the
treatment of a variety of hematological malig-
nancies.1-3 Although hematological toxicity is
the main adverse event associated with HD
Ara-C,4,5 increasing the dose of the drug to >2
g/m2 every 12 hours for 6 days may result in
skin, gastrointestinal and cerebellar toxicity.2,3
Conjunctivitis is observed in a significant pro-
portion of patients treated with HD Ara-C at
the dose of 2 or 3 g/m2 every 12 hours for 6
days. Toxicity to corneal epithelium and con-
junctiva is usually reversible but is often very
uncomfortable, especially when associated
with photophobia and ocular pain requiring
analgesic treatment.6-9 A number of prophy-
lactic regimens have been tested to prevent
HD Ara-C-induced conjunctivitis, including
the use of artificial tears, steroidal com-
pounds, or deoxycytidine.10,11 Steroidal eye
drops currently represent the standard pro-
phylaxis of cytarabine-induced conjunctivitis
which is, nevertheless, experienced by 40 to
65% of patients receiving HD Ara-C.12 While
the anti-inflammatory activity of steroids is
essentially due to inhibition of nuclear factor
kappa B13 and the arachidonic acid cascade,14
non-sterodial anti-inflammatory drugs
(NSAID) mainly act by inhibiting the cyclo-
oxygenase pathway.15 We, therefore, hypo-
thesized that adding a NSAID, acting with a
different mechanism of action, to the standard
steroidal prophylaxis might improve the ther-
apeutic efficacy of the standard prophylaxis.
To test this hypothesis, we prospectively
compared the incidence, severity, and dura-
tion of conjunctivitis in a series of 60 consecu-
tive patients who were randomized to receive
either dexamethasone eye drops or an associ-
ation of dexamethasone plus diclofenac eye
drops. 
Design and Methods
Patients
Between March 2003 and October 2004, 60
consecutive patients (28 males, 32 females)
with a median age of 49 years (range, 20 to 69
years) were enrolled in this study. The charac-
teristics of the patients at the time of study
entry are shown in Table 1. Criteria for exclu-
sion were: pre-existing eye infections, con-
junctivitis, or glaucoma. The study protocol
was approved by the Institutional Ethical
Committee and written informed consent
was obtained from each patient. 
Study drugs
Dexamethasone (Visumetazone®) was pur-
chased from Visufarma S.r.l. (Rome, Italy) as a
1 mg/mL solution; diclofenac sodium 0.1%
(Voltaren Ofta®) was purchased from Novartis
Farma SpA (Origgio, Italy).
Study design
At the time of HD Ara-C treatment 
(2 g/m2 every 12 hours, intravenously, on days
1-6), patients were randomized to receive top-
ical ophthalmic prophylaxis with either dex-
amethasone eye drops (two drops every 6
hours) (group A, n=29) or dexamethasone
(two drops every 6 hours) plus diclofenac eye
drops (two drops every 8 hours) (group B,
n=31). In both groups, ocular prophylaxis was
started on day –1 (24 hours before chemother-
apy administration) and continued until day
10. Group A patients developing conjunctivi-
tis of any grade were switched within 24
hours to receive diclofenac in addition to dex-
amethasone. 
Conjunctivitis grading
The conjunctivitis was graded according to
the Common Toxicity Criteria of the National
We investigated the efficacy of dexamethasone plus diclofenac eye drops as prophylaxis
for conjunctivitis induced by high-dose (HD) cytarabine (Ara-C). Sixty patients were random-
ized to receive either dexamethasone (group A, n=29) or dexamethasone plus diclofenac
(group B, n=31). Conjunctivitis was experienced by 13/29 (45%) patients in group A, and
4/31 (13%) patients in group B  (p≤0.009). Twelve out of 13 patients in group A who
developed ocular toxicity had grade 2-3 conjunctivitis whereas only one of four patients
affected in group B experienced a similar grade of conjunctivitis. The incidence and sever-
ity of HD Ara-C-induced conjunctivitis are significantly reduced by combined dexametha-
sone/ diclofenac prophylaxis. 
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Cancer Institute (NCI CTCAE v3.0). The criteria are: grade
1: simple eye irritation and discomfort not requiring anal-
gesic therapy; grade 2: previous symptoms plus photo-
phobia and inability to do normal activities. grade 3; con-
junctivitis episodes requiring the use of major analgesic
drugs. 
Statistical analysis
The data were analyzed with the statistical package
Prism 4.0 (GraphPad® Software, San Diego, CA, USA) run
on a Macintosh G4 personal computer. Fisher's exact test
was used to determine whether there was a non-random
association between two categorical variables. To test the
probability of significantly different means or medians,
Student’s t test for paired data (two-tail) or the Wilcoxon
matched pairs test was used, as appropriate. Differences
were considered statistically significant when the p value
was ≤0.05. 
Results and Discussion
Sixty consecutive patients receiving HD Ara-C 
(2 g/m2 every 12 hours, days 1-6) as part of a high-dose
sequential chemotherapy program16 were randomized to
receive topical ophthalmic prophylaxis with either dex-
amethasone eye drops (group A, n=29) or dexamethasone
plus diclofenac eye drops (group B, n=31). In both groups,
ocular prophylaxis was administered from day -1 to day
10. Group A patients who developed conjunctivitis were
given diclofenac in addition to dexamethasone. 
Table 2 summarizes the incidence, severity and dura-
tion of conjunctivitis in patients receiving dexamethasone
(group A) or dexamethasone plus diclofenac (group B).
The incidence of conjunctivitis was significantly higher in
group A than in group B, with 13 of 29 (45%) group A
patients and 4 of 31 (13%) group B patients experiencing
ocular toxicity (p≤0.009). Twelve out of 13 patients in
group A who developed ocular toxicity had grade 2-3
conjunctivitis with impairment of visual function and
ocular pain requiring analgesic therapy. In striking con-
trast, only one of four affected patients in group B (25%,
p<0.008) experienced a similar grade of conjunctivitis.
Median durations of conjunctivitis in group A (4.4 days,
range 2-8) and group B (3.2 days, range 2-5) patients were
not statistically different (p≥0.05). Since all group A
patients who experienced conjunctivitis of any grade
were switched to dexamethasone plus diclofenac therapy,
the similar duration of conjunctivitis in the two groups
essentially reflects the prompt resolution of conjunctivitis
by adding the NSAID to dexamethasone. 
Group A patients usually developed conjunctivitis dur-
ing chemotherapy (typically, on day 3 of cytarabine treat-
ment), whereas group B patients developed this adverse
effect after chemotherapy (typically, 2 to 3 days after
completing the course of cytarabine). This randomized
study aimed at comparing the efficacy of two prophylac-
tic regimens in preventing HD Ara-C-induced conjunc-
tivitis demonstrates that the combined administration of
dexamethasone plus diclofenac significantly reduces the
incidence and severity of conjunctivitis as compared to
dexamethasone alone. Over the last years, cytarabine has
been increasingly used for the treatment of hematologic
malignancies, and a spectrum of severe adverse events
has been related either to the dose delivered with each
infusion, or to the duration of the treatment. Con-
junctivitis is a side effect reported to occur in 40 to 85%
of patients receiving HD Ara-C.3 The etiology of cytara-
bine-induced corneal and conjunctival inflammation has
been related to concentration of cytarabine in tears,
which in turn seems to be dependent on cytarabine con-
centration in cerebrospinal fluid.6-9
Several prophylactic approaches have been investigated
for their ability to prevent cytarabine-induced conjunc-
tivitis. Higa et al.17 reported on a small series of 18 patients
receiving cytarabine 3 g/m2 every 12 hours for 6 days in
whom ocular prophylaxis with either prednisolone eye
drops or artificial tears was tested: no difference was
found between the two groups. Gococo et al.18 reported
that the prophylactic activities of prednisolone eye drops
and of a competitive inhibitor of cytosine arabinoside,
deoxycytidine, were similar. A small randomized trial
conducted by Bostrom et al. on 30 patients treated with
HD-cytarabine (3 g/m2 every 12 hours for 6 days) docu-
mented a superior activity of deoxycytidine over artificial
tears in preventing conjunctivitis.11 Currently, corticos-
Table 1. Characteristics of the patients at the time of the study.
Group A Group B p 
(n=29) (n=31)
Age
Median (yrs) 50 47 n.s.
Range (yrs) 26–69 20–62
Sex
Males 16 12 n.s.
Females 13 19 n.s.
Histology
DLBCL 16 17 n.s.
mantle cell lymphoma 2 2 n.s.
follicular cell lymphoma 4 4 n.s.
B-CLL/SLL 1 2 n.s.
refractory HL 2 3 n.s.
ALCL/PTCL 3 2 n.s.
Burkitt’s lymphoma 1 1 n.s.
Disease status
At diagnosis 16 22 n.s.
Refractory/relapsed 13 9 n.s.
Performance Status
0-1 29 31 n.s.
≥2 0 0
DLBCL: diffuse large B cell lymphoma;  B-CLL/SLL: B-chronic lymphocytic
leukemia/small lymphocytic lymphoma; HL: Hodgkin’s lymphoma;
ALCL/PTCL: anaplastic large cell lymphoma/peripheral T cell lymphoma;
n.s.: not significant.
Table 2. Incidence and severity of conjunctivitis episodes. 
Patients Patients G1* G2 G3 Median
(n) experiencing duration 
conjunctivitis (days)
Group A 29 13/29 (45%) 1 8 4 4
Group B 31 4/31 (13%) 3 0 1 3
*Grading according to NCI CTCAE v3.0. 
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teroids represent the standard prophylaxis for conjunctivi-
tis, with the alcohol form of dexamethasone being pre-
ferred to prednisolone due to a 5- to 7-fold higher anti-
inflammatory activity, and a greater capacity to penetrate
the lipid rich corneal epithelium.19
Although the most widely used method to grade con-
junctivitis is qualitative, and distinguishes conjunctivitis
cases as mild or severe, we found the recent NCI CTCAE
v3.0 accurate and exaustive enough. This approach pro-
vided us with a reliable and reproducible method for
grading conjunctivitis without having to use flanking oph-
thalmic examination with a slit lamp, or rose bengal stain-
ing.11,13
The majority of patients receiving steroid alone devel-
oped ocular toxicity earlier than patients receiving dexam-
ethasone plus diclofenac, suggesting that diclofenac is
responsible not only for reducing the incidence and sever-
ity of conjunctivitis but also for delaying the time to
onset. The lower incidence and severity of overall toxici-
ty experienced by patients in group B may be related to
the combined anti-inflammatory effect, but it may also
reflect the delayed onset of conjunctivitis and hence less
continued exposure to cytarabine after the toxicity had
occurred. Additionally, the rapid quiescence of toxicity
following addition of the NSAID in patients who devel-
oped ocular toxicity while on steroid alone suggests a dif-
ferent effect on the inflammatory process. Indeed both
drugs act on the arachidonic acid cascade, but the mecha-
nisms of action of dexamethasone and diclofenac are par-
tially different.14,15,20 Diclofenac inhibits the cyclo-oxyge-
nase pathway,15 whereas steroids inhibit nuclear factor κ
B and abrogate the arachidonic acid cascade by inhibiting
phospholipase A2 through the synthesis of lipocortins.13,14
Our efficacy data should prompt future studies compar-
ing the combination versus diclofenac as a single agent.
Such studies are also warranted in view of the results of a
recent randomized trial suggesting the superiority of
diclofenac over dexamethasone in the field of ophthalmo-
logical surgery.20 In conclusion, combined dexametha-
sone/diclofenac therapy is significantly superior to dex-
amethasone alone for preventing cytarabine-induced con-
junctivitis and should, therefore, become the standard
conjunctivitis prophylaxis in patients being treated with
HD Ara-C. 
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